Sound Bioventures

Today we announce that we have dosed the first patient in our Phase I/IIa trial of THEO-260 in patients with advanced-stage platinum-resistant ovarian cancer. THEO-260 is uniquely positioned to tackle the complex, immune supressed nature of advanced solid tumours.   This is a major milestone for Theolytics and brings us closer to delivering effective new treatment options for the many women who suffer from ovarian cancer, one of the leading causes of cancer-related deaths among women.   Read the full announcement: https://lnkd.in/ew26JC_B #OvarianCancer #ImmunoOncology #OncolyticImmunotherapy  

VarmX announces appointment of John Glasspool as CEO Leadership team fully strengthened to drive next phase of development We’re pleased to welcome international life sciences industry veteran John Glasspool as CEO of VarmX.    He brings over 30 years’ experience within the global biopharma industry, linking science and business. His expertise includes building and growing companies, fundraising and investing, licensing, partnering and commercialisation.    Jan Øhrstrøm, Chairman of VarmX, commented: “John’s knowledge of the coagulation and urgent care therapeutics space will be invaluable as we take VMX-C001 forward. Our leadership team is now significantly strengthened to enable us to drive the next stage of our growth with a Series C fundraise and a pivotal clinical trial.” See the news here: https://lnkd.in/dBFM3JrU #management #appointment #lifesciences #innovation +44 20 7390 0230 VarmX@vigoconsulting.com

"How Do You Do!": In collaboration with YVC - navigating mutual mentorship between CEOs and investors 📍 BIO-Europe® 🌍 Stockholm, Sweden 📆 November 4, 2024 🕖 17:00 – 18:00 Should mentorship be a two-way street between CEOs and biotech investors? This panel aims to uncover how CEOs and investors can significantly benefit from exchanging mentor roles and insights to drive collective success for biotech companies. Learn more about the dynamics of mutual mentorship, understand risks and rewards from engaging in reverse learning, and listen to investors and C-level professionals share real life experiences. Moderator: Philip Brainin, MD PhD MBA Panelists: Anta Gkelou Renee Aguiar-Lucander Bobby Soni Find out what else is on the agenda >> http://spr.ly/6044oqYfI #BIOEurope #Mentorship #CEOs #Investors YVC Collective

#BREAKING: Today, we are thrilled to announce the first participant has been dosed in the Phase I-IIa ArthemiR™ Trial of ATX-01 for Myotonic Dystrophy Type 1 (DM1), the industry’s first anti-microRNA therapeutic to be investigated in persons living with DM1. ATX-01 is an antimiR oligonucleotide designed to target microRNA 23b (miR-23b), which is involved in the pathogenesis of DM1. It has been demonstrated, in human DM1 primary myoblasts and in two murine models, that ATX-01 has a dual mechanism of action which reduces toxic DMPK mRNA and increases MBNL protein production. Click here to learn more: https://lnkd.in/gg2JWx3M Visit our #Patients page on our website too: https://lnkd.in/gVNxdQVH Learn more about the dual mechanism of our AntimiR™ technology here: https://lnkd.in/gnmFvjHv #RNAInnovation #MicroRNA #Biotech #MyotonicDystrophy #DM1 #FirstPatientDosed